Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
GILD [NASD]
Gilead Sciences Inc.
IndexS&P 500 P/E32.96 EPS (ttm)2.71 Insider Own0.50% Shs Outstand1.54B Perf Week0.37%
Market Cap137.18B Forward P/E11.03 EPS next Y8.10 Insider Trans10.70% Shs Float1.53B Perf Month10.01%
Income4.58B PEG1.17 EPS next Q1.73 Inst Own93.10% Short Float6.14% Perf Quarter22.60%
Sales13.67B P/S10.04 EPS this Y10.40% Inst Trans-0.04% Short Ratio7.65 Perf Half Y9.50%
Book/sh8.71 P/B10.26 EPS next Y23.03% ROA19.10% Target Price102.04 Perf Year49.61%
Cash/sh4.21 P/C21.21 EPS next 5Y28.20% ROE39.20% 52W Range55.96 - 90.98 Perf YTD18.95%
Dividend- P/FCF37.22 EPS past 5Y11.90% ROI18.70% 52W High-1.81% Beta0.72
Dividend %- Quick Ratio1.80 Sales past 5Y16.00% Gross Margin77.80% 52W Low59.63% ATR2.12
Employees6100 Current Ratio2.20 Sales Q/Q97.50% Oper. Margin47.90% RSI (14)61.71 Volatility3.48% 2.45%
OptionableYes Debt/Eq0.73 EPS Q/Q209.30% Profit Margin33.50% Rel Volume0.98 Prev Close89.33
ShortableYes LT Debt/Eq0.59 EarningsJul 23 AMC Payout0.00% Avg Volume12.25M Price89.33
Recom1.70 SMA203.28% SMA507.28% SMA20016.95% Volume0 Change0.00%
28-Apr-14Reiterated Maxim Group Buy $101 → $112
21-Feb-14Reiterated Barclays Overweight $90 → $95
10-Feb-14Reiterated Argus Buy $84 → $90
05-Feb-14Reiterated RBC Capital Mkts Outperform $90 → $96
05-Feb-14Reiterated Needham Buy $85 → $95
05-Feb-14Reiterated Maxim Group Buy $98 → $101
04-Feb-14Upgrade Robert W. Baird Neutral → Outperform $65 → $103
28-Jan-14Reiterated Deutsche Bank Buy $95 → $132
06-Jan-14Reiterated UBS Buy $80 → $102
02-Jan-14Reiterated Maxim Group Buy $89 → $98
20-Dec-13Reiterated RBC Capital Mkts Outperform $80 → $90
01-Nov-13Reiterated Argus Buy $70 → $84
30-Oct-13Reiterated RBC Capital Mkts Outperform $72 → $80
30-Oct-13Reiterated Barclays Overweight $68 → $74
26-Jul-13Reiterated Stifel Buy $65 → $75
26-Jul-13Reiterated RBC Capital Mkts Outperform $62 → $72
26-Jul-13Reiterated Barclays Overweight $65 → $68
26-Jul-13Downgrade Robert W. Baird Outperform → Neutral $55 → $65
13-Jun-13Upgrade Argus Hold → Buy
17-May-13Reiterated UBS Buy $63 → $67
23-Jul-14 08:45AM  Top Biotechnology Stocks Accesswire
07:50AM  Gilead Earnings Preview: Non-Sovaldi Sales Bogey May Be Unrealistic at Seeking Alpha
07:30AM  Stocks To Watch: Natus Medical, Gilead... at Seeking Alpha
07:07AM  Q2 2014 Gilead Sciences Earnings Release - 4:05 pm ET CCBN
22-Jul-14 07:08PM  This is What Happens When A New Drug Hits the Market and Nobody Knows What to Expect Yahoo Finance Blogs
07:08PM  This is What Happens When A New Drug Hits the Market and Nobody Knows What to Expect Yahoo Finance Blogs
05:17PM  [video] Earnings Preview: 3 Things to Watch at Bloomberg
05:03PM  Gilead Sciences Should Report $4B In Sovaldi Sales In Q2'14 at Seeking Alpha
05:02PM  3 Things You Need to Watch on Gilead Sciences Inc. Earnings Call at Motley Fool
03:20PM  Gilead's Pipeline Requires MacroGenics' ImmunoOncology Platform (M&A) at Seeking Alpha
02:29PM  What to Watch in The Day Ahead; Wednesday, July 23 Reuters
12:42PM  Alexion, 3 Other Top Biotechs Reporting Earnings at Investor's Business Daily
12:12PM  Gilead Expected to Post Sky-High Hep C Sales in June Quarter at TheStreet
11:38AM  Do This Drug's Sales Make J&J a Hepatitis C Powerhouse? at Motley Fool
10:37AM  HIV pills show more promise to prevent infection AP
10:20AM  Will Gilead (GILD) Earnings Disappoint in Q2 as Costs Rise? Zacks
21-Jul-14 05:02PM  Gilead Earnings: Can Sovaldi Reach $3 Billion? at Motley Fool
04:09PM  Biogen Shares Rebound As Street Has A Change Of Heart at Investor's Business Daily
03:04PM  Why I'm Shorting Gilead: Sentiment Is Too Positive Ahead of Earnings at TheStreet
03:04PM  [video]Why I'm Shorting Gilead: Sentiment Is Too Positive Ahead of Earnings at TheStreet
02:00PM  [video] Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People at TheStreet
01:33PM  Big Week of Earnings for Big Biotech ETF ETF Trends
10:41AM  Hepatitis C Spurs Unusual Patent Wars Among Big Drug Makers at The Wall Street Journal
10:38AM  Gilead Sciences: Sovaldi's a Blockbuster, the Question is How Big at Barrons.com
09:49AM  Gilead (GILD) Reaches New Lifetime High Today at TheStreet
08:22AM  How Will Gilead Sciences (GILD) Stock Be Affected By Solvadi Hepatitis C Finding? at TheStreet
06:31AM  The Morning Ledger: Dodd-Frank, Still Unfinished, Comes Under Republican Fire at The Wall Street Journal
03:05AM  5 Strong Stocks To Buy Before Earnings at Seeking Alpha
01:08AM  [$$] Lucrative Drug Niche Sparks Legal Scramble at The Wall Street Journal
20-Jul-14 03:36PM  CVS officials say Sovaldi pricing in line with history, but unsustainable at MarketWatch
10:10AM  Gilead Drug Combination Cures Hepatitis C in HIV Patients Bloomberg
10:10AM  Gilead Drug Combination Cures Hepatitis C in HIV Patients at Bloomberg
19-Jul-14 08:02AM  Facebook, Gilead Headline IBD 50's Top 5 Earnings at Investor's Business Daily
18-Jul-14 06:30PM  Politics fade as earnings take over at CNBC
06:08PM  Investors Focus On Earnings Rather Than Geopolitical Tensions Benzinga
05:02PM  Gilead Sciences Stock's Huge Hidden Opportunity at Motley Fool
05:02PM  Gilead: 50% Upside From Here at Seeking Alpha
02:57PM  Stocks Up In Late Trade; AerCap Nears Resistance at Investor's Business Daily
12:41PM  Gilead Sciences: Time For a Dividend? at Barrons.com
11:53AM  Stocks Add To Gains; Under Armour Rebounds at Investor's Business Daily
08:24AM  An Open Letter To Janet Yellen: Is There A Biotech Bubble? at Forbes
17-Jul-14 10:04PM  Do Johnson & Johnson's Results Suggest a Pop or Drop for Gilead Sciences? at Motley Fool
04:11PM  Oregon to Pharma: Let's Make a Deal on Hepatitis C Drugs at The Wall Street Journal
11:47AM  Gilead Sciences: Does Anyone Think It's Not Going to Beat? at Barrons.com
10:40AM  Cramer: The Tell of When to Sell at TheStreet
09:42AM  Yellen Fire In The Biotech Theater at Forbes
08:26AM  Will Gilead's Hepatitis C Drug Bust State Budgets? at The Wall Street Journal
07:10AM  The Tell of When to Sell TheStreet
16-Jul-14 05:02PM  Gilead Stock Earnings: What to Watch at Motley Fool
05:00PM  Gilead Sciences to Release Second Quarter 2014 Financial Results on Wednesday, July 23, 2014 Business Wire
02:02PM  Keep Calm and Carry On, J&J at Motley Fool
11:09AM  Jim Cramer's Stop Trading: Speculation Isn't Bad at TheStreet
09:55AM  Gilead Sciences: How Good Will Earnings Be? at Barrons.com
08:49AM  Biotech Stock Roundup: AbbVie Woos Shire with Revised Offer, Sarepta Slips on Eteplirsen Data Zacks
15-Jul-14 03:15PM  J&J Earnings Beat Estimates, But Guidance Mixed at Investor's Business Daily
01:40PM  [video] Next global epidemic? at CNBC
12:15PM  J&J's Strong 2Q Led by Pharmaceuticals Morningstar
12:07PM  Johnson & Johnson Earnings Good News For Gilead Sciences at Barrons.com
11:15AM  Fed's Yellen: Social Media, Biotech Valuations 'Substantially Stretched' at Forbes
08:06AM  This liver disease could rival hepatitis C at CNBC
08:06AM  Market for this liver drug could rival hepatitis C at CNBC
14-Jul-14 05:01PM  1 Hidden Blockbuster Lurking in Merck's Pipeline? at Motley Fool
01:28PM  Biotech Better Beat EarningsOr Else at Barrons.com
10:30AM  Hefty Price Tag of Gilead's Sovaldi Questioned Again Zacks
11-Jul-14 10:58PM  [$$] Senate Committee Is Investigating Pricing of Hepatitis C Drug at The Wall Street Journal
10:43PM  [$$] Senate Committee Is Investigating Pricing of Hepatitis C Drug at The Wall Street Journal
09:39PM  [$$] Senate Committee Is Investigating Pricing of Hepatitis C Drug at The Wall Street Journal
08:29PM  [$$] Senate Committee Is Investigating Pricing of Hepatitis C Drug at The Wall Street Journal
06:18PM  [$$] Senators Investigating Hepatitis C Drug Pricing at The Wall Street Journal
05:46PM  France Not Retreating from Gilead Sciences at Motley Fool
05:45PM  [$$] Senators Investigating Hepatitis C Drug Pricing at The Wall Street Journal
05:28PM  U.S. senators ask Gilead Sciences to explain high cost of hepatitis C drug at San Jose Mercury News
05:01PM  1 Drug More Important to Gilead Than Sovaldi at Motley Fool
04:49PM  [$$] Senators Investigating Hepatitis C Drug Pricing at The Wall Street Journal
04:06PM  [$$] Senators Investigating Hepatitis C Drug Pricing at The Wall Street Journal
03:21PM  Gilead Faces New Pressure From U.S. Senators & Europe Over Hep C Pricing at The Wall Street Journal
03:06PM  Gilead Sciences: The Senate Just Wrote Me a Letter at Barrons.com
02:26PM  Gilead's high pricing of Sovaldi draws inquiry from Senate committee at MarketWatch
01:36PM  Gilead's high pricing of Sovaldi draws inquiry from Senate committee at MarketWatch
01:08PM  Europe, US officials pressure Gilead to lower cost of hep C treatment at San Jose Mercury News
12:05PM  Stocks Mixed In Low-Volume Session; Facebook Firms Up at Investor's Business Daily
11:35AM  Senators Ask Gilead To Explain Sovaldi Pricing at Investor's Business Daily
11:25AM  Gilead Faces New Pressure From U.S. Senators & Europe Over Hep C Pricing at The Wall Street Journal
11:15AM  U.S. senators ask Gilead to explain cost of Sovaldi hepatitis drug Reuters
10:48AM  U.S. Senators Ask Gilead to Explain $84,000 Hep C Drug Pricing at Bloomberg
10:38AM  Gilead Faces New Pressure From U.S. Senators & Europe Over Hep C Pricing at The Wall Street Journal
10:20AM  Senators ask Gilead to explain cost of Sovaldi hepatitis drug Reuters
09:48AM  Senators make new request to Gilead for Sovaldi pricing details theflyonthewall.com
09:46AM  Trade-Ideas: Gilead (GILD) Is Today's New Lifetime High Stock at TheStreet
08:52AM  How Gilead Sciences Can Deliver A Double: Part Two at Forbes
07:36AM  Johnson & Johnson Q2 EPS likely to exceed expectations, says Bernstein theflyonthewall.com
10-Jul-14 05:02PM  Are These the Best Big Biotech Stocks for Your Portfolio? at Motley Fool
01:52PM  Bull rolls on, but opportunities start to dwindle at MarketWatch
12:41PM  [video] Trader sells Citi, buys SunTrust at CNBC
11:35AM  Gilead Sciences Can Hit Par By The End Of The Year at Seeking Alpha
10:59AM  A Pre-Earnings Update On Gilead at Seeking Alpha
10:25AM  Gilead Sciences: Cause For Concern? at Seeking Alpha
10:07AM  Regeneron Picked a Heck of a Day to Announce Good News at Barrons.com
09-Jul-14 09:30PM  Medical Breakthroughs And Credit Markets at Forbes
08-Jul-14 02:42PM  Alexion Pharma Looks To Life Beyond Its Blockbuster at Investor's Business Daily
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of life threatening diseases in North America, South America, Europe, and the Asia-Pacific. The company's products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Sovaldi, Viread, and Hepsera products for the treatment of liver disease. It also offers Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; Vistide, an antiviral injection for the treatment of cytomegalovirus retinitis in adult patients with AIDS; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages for the treatment of HIV, liver, oncology/inflammation, cardiovascular, and respiratory diseases. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaborations with BMS, Janssen, and Japan Tobacco to develop and commercialize various products. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Carter Paul RutherfordEVP Commercial OpsJul 08Option Exercise26.9916,728451,48947,433Jul 10 01:41 PM
Carter Paul RutherfordEVP Commercial OpsJul 08Sale86.4516,7281,446,07430,705Jul 10 01:41 PM
Whitley Richard JamesDirectorJul 01Option Exercise26.995,000134,95020,641Jul 02 04:24 PM
MARTIN JOHN CChairman and CEOJul 01Option Exercise8.01140,6251,125,7034,570,012Jul 03 02:28 PM
Alton Gregg HEVP, Corp & Med AffairsJul 01Option Exercise23.6131,000731,853159,694Jul 03 03:14 PM
MARTIN JOHN CChairman and CEOJul 01Sale84.84140,62511,929,9614,429,387Jul 03 02:28 PM
Alton Gregg HEVP, Corp & Med AffairsJul 01Sale84.1233,0002,776,076126,694Jul 03 03:14 PM
Whitley Richard JamesDirectorJul 01Sale83.655,000418,25015,641Jul 02 04:24 PM
Washington Robin LEVP, CFOJun 30Sale83.9810,400873,40346,774Jul 02 01:44 PM
Cogan John FrancisDirectorJun 23Option Exercise14.345,00071,68847,405Jun 25 01:51 PM
Cogan John FrancisDirectorJun 23Sale81.825,000409,12342,405Jun 25 01:51 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJun 16Option Exercise16.4090,0001,475,550209,302Jun 18 04:33 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJun 16Sale80.9090,0007,280,784119,302Jun 18 04:33 PM
Carter Paul RutherfordEVP Commercial OpsJun 09Option Exercise26.9916,728451,48947,433Jun 11 12:59 PM
Carter Paul RutherfordEVP Commercial OpsJun 09Sale79.4316,7281,328,64530,705Jun 11 12:59 PM
Washington Robin LEVP, CFOJun 04Sale82.526,426530,27457,174Jun 05 05:46 PM
Whitley Richard JamesDirectorJun 02Option Exercise26.995,000134,95020,641Jun 04 05:18 PM
Alton Gregg HEVP, Corp & Med AffairsJun 02Option Exercise23.6031,000731,600161,694Jun 04 05:21 PM
MARTIN JOHN CChairman and CEOJun 02Option Exercise8.01140,6251,125,7034,570,012Jun 04 02:48 PM
Whitley Richard JamesDirectorJun 02Sale80.955,000404,75015,641Jun 04 05:18 PM
Alton Gregg HEVP, Corp & Med AffairsJun 02Sale81.3533,0002,684,514128,694Jun 04 05:21 PM
MARTIN JOHN CChairman and CEOJun 02Sale81.32140,62511,435,8364,429,387Jun 04 02:48 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOMay 14Option Exercise16.4090,0001,475,550209,302May 16 02:52 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOMay 14Sale80.6590,0007,258,752119,302May 16 02:52 PM
Carter Paul RutherfordEVP Commercial OpsMay 10Option Exercise0.005,000021,290May 13 02:27 PM
MILLIGAN JOHN FPresident and COOMay 08Option Exercise8.01100,000800,5001,038,048May 09 06:58 PM
Alton Gregg HEVP, Corp & Med AffairsMay 08Option Exercise23.3340,000933,132170,694May 12 03:38 PM
Alton Gregg HEVP, Corp & Med AffairsMay 08Sale80.0040,0003,200,000130,694May 12 03:38 PM
Washington Robin LEVP, CFOMay 06Option Exercise24.913,00074,71552,832May 08 07:13 PM
Washington Robin LEVP, CFOMay 06Sale79.913,000239,73049,832May 08 07:13 PM
Alton Gregg HEVP, Corp & Med AffairsMay 01Option Exercise21.5811,000237,325143,694May 05 05:23 PM
Whitley Richard JamesDirectorMay 01Option Exercise26.995,000134,95017,778May 05 05:36 PM
MARTIN JOHN CChairman and CEOMay 01Option Exercise8.01140,6251,125,7034,570,012May 05 05:52 PM
Whitley Richard JamesDirectorMay 01Sale78.635,000393,15012,778May 05 05:36 PM
Alton Gregg HEVP, Corp & Med AffairsMay 01Sale79.0813,0001,028,024130,694May 05 05:23 PM
MARTIN JOHN CChairman and CEOMay 01Sale79.02140,62511,112,0344,429,387May 05 05:52 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOApr 14Option Exercise16.4090,0001,475,550209,302Apr 16 12:34 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOApr 14Sale67.0390,0006,032,482119,302Apr 16 12:34 PM
Cogan John FrancisDirectorApr 08Option Exercise14.345,00071,68844,542Apr 10 02:52 PM
Carter Paul RutherfordEVP Commercial OpsApr 08Option Exercise24.4316,728408,68945,290Apr 10 03:52 PM
Cogan John FrancisDirectorApr 08Sale70.555,000352,75539,542Apr 10 02:52 PM
Carter Paul RutherfordEVP Commercial OpsApr 08Sale70.5316,7281,179,78228,562Apr 10 03:52 PM
MARTIN JOHN CChairman and CEOApr 01Option Exercise8.01140,6251,125,7034,570,012Apr 03 03:20 PM
Whitley Richard JamesDirectorApr 01Option Exercise26.995,000134,95018,116Apr 03 04:00 PM
Alton Gregg HEVP, Corp & Med AffairsApr 01Option Exercise21.5811,000237,325145,694Apr 03 03:20 PM
MARTIN JOHN CChairman and CEOApr 01Sale73.26140,62510,302,0284,429,387Apr 03 03:20 PM
Alton Gregg HEVP, Corp & Med AffairsApr 01Sale73.2013,000951,640132,694Apr 03 03:20 PM
Whitley Richard JamesDirectorApr 01Sale73.095,000365,45013,116Apr 03 04:00 PM
Cogan John FrancisDirectorMar 14Option Exercise14.3414,000200,72553,542Mar 18 12:56 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOMar 14Option Exercise16.4090,0001,475,550209,302Mar 18 01:36 PM
Cogan John FrancisDirectorMar 14Sale76.4414,0001,070,10139,542Mar 18 12:56 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOMar 14Sale75.8990,0006,829,705119,302Mar 18 01:36 PM
Carter Paul RutherfordEVP Commercial OpsMar 10Option Exercise21.5816,728360,90745,290Mar 12 01:39 PM
Carter Paul RutherfordEVP Commercial OpsMar 10Sale79.3216,7281,326,83328,562Mar 12 01:39 PM
Alton Gregg HEVP, Corp & Med AffairsMar 03Option Exercise21.5831,000668,825117,484Mar 05 02:50 PM
MARTIN JOHN CChairman and CEOMar 03Option Exercise8.01140,6251,125,7034,397,860Mar 05 02:51 PM
Alton Gregg HEVP, Corp & Med AffairsMar 03Sale81.8433,0002,700,68784,484Mar 05 02:50 PM
MARTIN JOHN CChairman and CEOMar 03Sale81.74140,62511,495,3264,257,235Mar 05 02:51 PM
Washington Robin LEVP, CFOFeb 28Option Exercise22.3030,600682,49080,432Mar 04 09:09 PM
Carter Paul RutherfordEVP Commercial OpsFeb 28Option Exercise24.0099,0002,375,550114,842Mar 04 02:56 PM
Carter Paul RutherfordEVP Commercial OpsFeb 28Sale83.5599,0008,271,93515,842Mar 04 02:56 PM
Washington Robin LEVP, CFOFeb 28Sale83.6530,6002,559,63549,832Mar 04 09:09 PM
MOORE NICHOLAS GDirectorFeb 26Option Exercise26.6220,000532,30020,000Feb 28 12:50 PM
MOORE NICHOLAS GDirectorFeb 26Sale84.0520,0001,681,0700Feb 28 12:50 PM
Washington Robin LEVP, CFOFeb 21Option Exercise23.605,000118,00054,832Feb 25 03:41 PM
Washington Robin LEVP, CFOFeb 21Sale83.245,000416,21849,832Feb 25 03:41 PM
MOORE NICHOLAS GDirectorFeb 19Option Exercise22.0219,068419,78219,068Feb 21 02:32 PM
MOORE NICHOLAS GDirectorFeb 19Sale83.1219,0681,584,9900Feb 21 02:32 PM
Washington Robin LEVP, CFOFeb 19Sale83.3696880,69249,832Feb 21 03:41 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOFeb 14Option Exercise14.5090,0001,305,225158,124Feb 19 02:09 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOFeb 14Sale81.3690,0007,322,22268,124Feb 19 02:09 PM
Carter Paul RutherfordEVP Commercial OpsFeb 10Option Exercise21.5816,728360,90731,861Feb 12 04:44 PM
Carter Paul RutherfordEVP Commercial OpsFeb 10Sale79.1016,7281,323,19815,133Feb 12 04:44 PM
Alton Gregg HEVP, Corp & Med AffairsFeb 03Option Exercise21.5831,000668,825118,516Feb 05 06:34 PM
MARTIN JOHN CChairman and CEOFeb 03Option Exercise8.01140,6251,125,7034,396,892Feb 05 06:53 PM
Alton Gregg HEVP, Corp & Med AffairsFeb 03Sale80.7833,0002,665,59385,516Feb 05 06:34 PM
MARTIN JOHN CChairman and CEOFeb 03Sale79.96140,62511,244,0894,256,267Feb 05 06:53 PM
YOUNG KEVINEVP, Commercial OperationsJan 23Option Exercise16.40100,0001,639,500316,418Jan 27 08:07 PM
YOUNG KEVINEVP, Commercial OperationsJan 23Sale81.44100,0008,144,150216,418Jan 27 08:07 PM
Alton Gregg HEVP, Corp & Med AffairsJan 21Option Exercise19.94120,0002,392,393152,938Jan 22 07:15 PM
Alton Gregg HEVP, Corp & Med AffairsJan 21Sale80.00120,0009,600,00032,938Jan 22 07:15 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJan 14Option Exercise14.5090,0001,305,22590,000Jan 16 02:15 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJan 14Sale74.2390,0006,681,1470Jan 16 02:15 PM
Alton Gregg HEVP, Corp & Med AffairsJan 02Option Exercise19.11111,0002,121,519145,938Jan 06 05:39 PM
MARTIN JOHN CChairman and CEOJan 02Option Exercise8.01140,6251,125,7034,197,746Jan 06 05:38 PM
Washington Robin LSVP, CFOJan 02Option Exercise22.4935,600800,49035,600Jan 06 05:39 PM
Alton Gregg HEVP, Corp & Med AffairsJan 02Sale75.01113,0008,476,56432,938Jan 06 05:39 PM
MARTIN JOHN CChairman and CEOJan 02Sale75.02140,62510,550,1804,057,121Jan 06 05:38 PM
Washington Robin LSVP, CFOJan 02Sale75.0335,6002,671,2140Jan 06 05:39 PM
YOUNG KEVINEVP, Commercial OperationsDec 20Option Exercise16.4075,0001,229,625236,840Dec 24 01:41 PM
YOUNG KEVINEVP, Commercial OperationsDec 20Sale74.1975,0005,564,453161,840Dec 24 01:41 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSODec 16Option Exercise14.5090,0001,305,22590,000Dec 18 02:16 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSODec 16Sale71.7590,0006,457,9410Dec 18 02:16 PM
MARTIN JOHN CChairman and CEODec 02Option Exercise7.63282,2422,154,2124,339,363Dec 04 03:55 PM
MARTIN JOHN CChairman and CEODec 02Sale74.26282,24220,960,6974,057,121Dec 04 03:55 PM
MILLIGAN JOHN FPresident and COONov 25Option Exercise7.8125,588199,954590,362Nov 26 06:20 PM
YOUNG KEVINEVP, Commercial OperationsNov 22Option Exercise16.4075,0001,229,625236,840Nov 25 03:25 PM
YOUNG KEVINEVP, Commercial OperationsNov 22Sale74.3475,0005,575,549161,840Nov 25 03:25 PM
MILLIGAN JOHN FPresident and COONov 21Option Exercise7.63395,6343,019,677960,408Nov 25 01:16 PM
DAVIGNON ETIENNEDirectorNov 21Sale71.579,778699,7931,160,186Nov 25 03:13 PM